Study shows that removing the protein IGF2BP3 slows cancer growth and increases chances of survival of rare types of leukaemia in mice.
List view / Grid view
Acute lymphoblastic leukaemia
Chimeric antigen receptor (CAR) T and natural killer (NK) therapies may become the future of cancer treatment. Dr Jim Ross explains how bioelectronic assays are a non-invasive, label-free approach built for real-time, dynamic assessment of cell therapy potency.
A new study into the molecular causes of acute lymphoblastic leukaemia could lead to a new target for therapy.
Scientists in the US have developed a promising new CAR T-cell therapy that targets the BAFF-R protein, which has demonstrated superior cancer destruction to existing FDA-approved CAR-T therapies.
Researchers have discovered a new combination therapy to treat drug-resistant acute lymphoblastic leukaemia, tested in pre-clinical trials.
A single leukemic cell has become resistant to CAR-T therapy after unknowingly engineered with the leukemia-targeting CAR lentivirus...
Enzyme therapy is a promising form of cancer treatment. The specific nature of enzyme and substrate interaction gives enzyme therapy an edge compared to standard non-specific therapies such as radiation and chemotherapy. However, since most of these enzymes are of a foreign nature, the delivery of these immunogenic enzymes has…